A Phase 2 interventional study of Abemaciclib and Tamoxifen in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 59 sites in 14 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.
Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 13th largest by enrollment, is one of 5 that started in 2016, is one of 27 in phase 2, and was the 8th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Japanese Foundation for Cancer Research · Sites in Japan
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 29 · Phase 3 11 · Phase 4 8
First in 2014; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 55 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 26th largest by enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2016, is one of 41 in phase 2, and was the 55th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
6 of the studies testing abemaciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341621Phase 3Fudan UniversityChemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib | 2027-02-25 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT06207734Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDiscontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | 2027-01-10 |
| NCT04614194University of Texas Southwestern Medical CenterSingle Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | 2027-04-15 |
| NCT04305834City of Hope Medical CenterAbemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 55 studies testing abemaciclib in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib · Drug: Tamoxifen
Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib · Drug: Prophylactic Loperamide
Administered orally
Also known as: LY2835219
Administered orally
Administered orally
Progression Free Survival (PFS)
Progression-free survival time was measured from the date of randomization to the date of investigator-determined objective progression as defined by RECIST v1.1, or death from any cause, whichever occurred first. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.
Time frame: Baseline to Objective Disease Progression or Death from Any Cause (Up to 21 Months)
Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)
Objective response rate was defined as the percentage of participants with CR or PR according to RECIST v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD (longest diameter) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Time frame: Baseline to Objective Disease Progression (Up to 21 Months)
Duration of Response (DoR)
DoR is defined as the time from the date of first evidence of a CR or PR to the date of objective progression or death from any cause, whichever is earlier as defined by Recist v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Time frame: Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 21 Months)
Overall Survival (OS)
Time frame: Baseline to Death from Any Cause (Approximately 36 Months)
Pharmacokinetics (PK): Mean Single Dose Concentration of Abemaciclib and Its Metabolites
Mean single dose concentrations of Abemaciclib and its metabolites (M2 \& M20) are reported.
Time frame: Cycle (C) 1 Day (D) 1 post dose
Pharmacokinetics (PK): Steady State Concentration of Abemaciclib and Its Metabolites
Mean steady state concentrations of Abemaciclib and its metabolites (M2 \& M20) are reported. C=Cycle D= Day
Time frame: Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1 post dose
PK: Mean Single Dose Concentration of Tamoxifen and Endoxifen
Mean single dose concentrations of Tamoxifen and its metabolite (Endoxifen) were reported.
Time frame: Cycle 1 Day 1 post dose
PK: Multiple Dose Concentration of Tamoxifen and Endoxifen
Mean multiple dose concentrations of Tamoxifen and its metabolite (Endoxifen) were reported.
Time frame: Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1 post dose
Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.
Time frame: Baseline, 21 Months
Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours and typical completion time for this instrument is less than 5 minutes.
Time frame: Baseline, 21 Months
| Milestone | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| Started | 78 | 79 | 77 |
| Received at least one dose of study drug | 78 | 79 | 77 |
| Completed | 21 | 30 | 30 |
| Not completed | 57 | 49 | 47 |
| Withdrew: Withdrawal by subject | 8 | 5 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 | 2 |
| Withdrew: On study treatment/follow-up | 48 | 42 | 41 |
Progression-free survival time was measured from the date of randomization to the date of investigator-determined objective progression as defined by RECIST v1.1, or death from any cause, whichever occurred first. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.
| Months | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| Progression Free Survival (PFS) | 9.07 (6.90 to 10.95) | 6.48 (4.77 to 9.21) | 7.43 (5.42 to 9.17) |
Objective response rate was defined as the percentage of participants with CR or PR according to RECIST v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD (longest diameter) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
| Percentage of participants | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | 34.6 (24.1 to 45.2) | 24.1 (14.6 to 33.5) | 32.5 (22 to 42.9) |
DoR is defined as the time from the date of first evidence of a CR or PR to the date of objective progression or death from any cause, whichever is earlier as defined by Recist v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
| Months | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| Duration of Response (DoR) | 7.40 (3.88 to 9.27) | 9.21 (3.72 to NA) | 7.46 (5.56 to 10.92) |
Results for this outcome have not been posted.
Mean single dose concentrations of Abemaciclib and its metabolites (M2 \& M20) are reported.
| Nanogram per Millilitre (ng/mL) | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| Abemaciclib (C1D1) | 10.9 ± 231 | 3.05 ± 95.4 | 8.59 ± 440 |
| M2 (C1D1) | 6.05 ± 123 | 2.14 ± 60.1 | 6.85 ± 237 |
| M20 (C1D1) | 6.50 ± 132 | 2.54 ± 54.5 | 7.91 ± 220 |
Mean steady state concentrations of Abemaciclib and its metabolites (M2 \& M20) are reported. C=Cycle D= Day
| Nanogram per Millilitre (ng/mL) | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| Abemaciclib (C1D15) | 214 ± 66.4 | 256 ± 58.8 | 314 ± 74.3 |
| M2 (C1D15) | 96.5 ± 53.9 | 108 ± 45.6 | 147 ± 47.1 |
| M20 (C1D15) | 180 ± 51.1 | 199 ± 41.0 | 251 ± 48.5 |
| Abemaciclib (C2D1) | 98.9 ± 196 | 182 ± 129 | 220 ± 154 |
| M2 (C2D1) | 56.1 ± 88.0 | 85.4 ± 62.1 | 105 ± 98.5 |
| M20 (C2D1) | 100 ± 103 | 149 ± 78.9 | 164 ± 171 |
| Abemaciclib (C2D15) | 135 ± 115 | 157 ± 173 | 175 ± 136 |
| M2 (C2D15) | 62.3 ± 79.0 | 71.7 ± 97.9 | 95.4 ± 73.9 |
| M20 (C2D15) | 120 ± 76.2 | 128 ± 121 | 154 ± 101 |
| Abemaciclib (C3D1) | 125 ± 64.3 | 177 ± 42.0 | 207 ± 49 |
| M2 (C3D1) | 60.6 ± 39.6 | 78.4 ± 38.2 | 95.8 ± 44.2 |
| M20 (C3D1) | 109 ± 39.4 | 146 ± 37.7 | 171 ± 36.6 |
Mean single dose concentrations of Tamoxifen and its metabolite (Endoxifen) were reported.
| ng/mL | 150mg Abemaciclib + 20mg Tamoxifen |
|---|---|
| Tamoxifen (C1D1) | 7.47 ± 116 |
| Endoxifen (C1D1) | NA ± NA |
Mean multiple dose concentrations of Tamoxifen and its metabolite (Endoxifen) were reported.
| ng/mL | 150mg Abemaciclib + 20mg Tamoxifen |
|---|---|
| Tamoxifen (C1D15) | 84.5 ± 41.6 |
| Endoxifen (C1D15) | 4.76 ± 99.7 |
| Tamoxifen (C2D1) | 98.7 ± 50.2 |
| Endoxifen (C2D1) | 7.41 ± 89.5 |
| Tamoxifen (C2D15) | 109 ± 51.9 |
| Endoxifen (C2D15) | 9.17 ± 73.7 |
| Tamoxifen (C3D1) | 112 ± 60.2 |
| Endoxifen (C3D1) | 10.3 ± 84.8 |
The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.
| score on a scale | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| Global Health Status | 1.56 ± 1.83 | 4.56 ± 1.90 | -2.77 ± 1.91 |
| Functional Scales (Physical Functioning) | -2.01 ± 1.59 | -1.05 ± 1.68 | -2.65 ± 1.68 |
| Functional Scales (Role Functioning) | -0.44 ± 2.18 | -3.95 ± 2.30 | -5.87 ± 2.29 |
| Functional Scales (Emotional Functioning) | 4.40 ± 1.88 | 2.58 ± 1.95 | 1.86 ± 1.95 |
| Functional Scale (Cognitive Functioning) | 0.14 ± 1.37 | -1.31 ± 1.44 | -2.39 ± 1.43 |
| Functional Scales (Social Functioning) | 3.23 ± 2.08 | -0.53 ± 2.16 | -0.94 ± 2.16 |
| Symptom Scales (Fatigue) | 2.39 ± 2.05 | 2.77 ± 2.15 | 4.0 ± 2.16 |
| Symptom Scales (Nausea and Vomiting) | 5.59 ± 1.63 | 5.30 ± 1.73 | 5.09 ± 1.71 |
| Symptom Scales (Pain) | -3.09 ± 2.20 | -1.43 ± 2.30 | -2.01 ± 2.29 |
| Symptom Scales (Dyspnoea) | 4.21 ± 1.79 | -3.49 ± 1.89 | -2.0 ± 1.87 |
| Symptom Scales (Insomnia) | -5.02 ± 2.21 | -3.43 ± 2.36 | -2.98 ± 2.35 |
| Symptom Scales (Appetite Loss) | 5.82 ± 2.38 | 1.87 ± 2.50 | 7.76 ± 2.50 |
| Symptom Scales (Constipation) | -0.28 ± 1.57 | -6.29 ± 1.71 | 0.08 ± 1.67 |
| Symptom Scales (Diarrhoea) | 13.31 ± 1.97 | 20.17 ± 2.10 | 17.43 ± 2.09 |
| Symptom Scales (Functional Difficulties) | -7.56 ± 2.00 | -3.81 ± 2.08 | -0.09 ± 2.07 |
mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours and typical completion time for this instrument is less than 5 minutes.
| score on a scale | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| Pain at its Worst in Last 24 Hours | -0.53 ± 0.20 | -0.43 ± 0.21 | -0.43 ± 0.21 |
| Pain at its Least in Last 24 Hours | -0.09 ± 0.15 | -0.01 ± 0.16 | 0.14 ± 0.16 |
| Pain on the Average | -0.34 ± 0.16 | -0.20 ± 0.17 | -0.11 ± 0.17 |
| Pain Right Now | -0.28 ± 0.17 | -0.18 ± 0.17 | -0.04 ± 0.17 |
| Mean Interference Score | -0.09 ± 0.18 | 0.03 ± 0.18 | 0.16 ± 0.18 |
Collected over Up to 21 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 150mg Abemaciclib + 20mg Tamoxifen | 18/78 (23.1%) | 16/78 (20.5%) | 73/78 (93.6%) |
| 150mg Abemaciclib | 28/79 (35.4%) | 16/79 (20.3%) | 77/79 (97.5%) |
| 200mg Abemaciclib + 2mg Prophylactic Loperamide | 29/77 (37.7%) | 21/77 (27.3%) | 75/77 (97.4%) |
| Event | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 0/78 | 3/79 | 0/77 |
| NauseaGastrointestinal disorders | 0/78 | 1/79 | 2/77 |
| VomitingGastrointestinal disorders | 1/78 | 1/79 | 2/77 |
| AstheniaGeneral disorders | 2/78 | 0/79 | 1/77 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/78 | 2/79 | 1/77 |
| NeutropeniaBlood and lymphatic system disorders | 0/78 | 2/79 | 0/77 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/78 | 2/79 | 0/77 |
| PyrexiaGeneral disorders | 1/78 | 2/79 | 1/77 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/78 | 2/79 | 0/77 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/78 | 0/79 | 1/77 |
| Event | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 41/78 | 53/79 | 47/77 |
| NauseaGastrointestinal disorders | 24/78 | 26/79 | 33/77 |
| AnaemiaBlood and lymphatic system disorders | 30/78 | 24/79 | 31/77 |
| ConstipationGastrointestinal disorders | 10/78 | 9/79 | 25/77 |
| Neutrophil count decreasedInvestigations | 11/78 | 21/79 | 22/77 |
| Platelet count decreasedInvestigations | 8/78 | 9/79 | 22/77 |
| FatigueGeneral disorders | 22/78 | 17/79 | 21/77 |
| NeutropeniaBlood and lymphatic system disorders | 21/78 | 20/79 | 18/77 |
| VomitingGastrointestinal disorders | 14/78 | 20/79 | 20/77 |
| Decreased appetiteMetabolism and nutrition disorders | 20/78 | 12/79 | 17/77 |
| Age, Continuous(years) | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide | Total |
|---|---|---|---|---|
| Mean | 54.28 ± 12.47 | 56.18 ± 12.24 | 55.86 ± 11.03 | 55.44 ± 11.91 |
| Sex: Female, Male(Participants) | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide | Total |
|---|---|---|---|---|
| Female | 78 | 79 | 77 | 234 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide | Total |
|---|---|---|---|---|
| Hispanic or Latino | 16 | 20 | 21 | 57 |
| Not Hispanic or Latino | 55 | 45 | 46 | 146 |
| Unknown or Not Reported | 7 | 14 | 10 | 31 |
| Race (NIH/OMB)(Participants) | 150mg Abemaciclib + 20mg Tamoxifen | 150mg Abemaciclib | 200mg Abemaciclib + 2mg Prophylactic Loperamide | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 3 | 4 | 11 |
| Asian | 8 | 6 | 10 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 2 | 5 |
| White | 63 | 64 | 60 | 187 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 4 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2016 to primary completion in Jun 2018, 21 months.
Results were first posted in Jul 2019, 1 year after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 21 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib